Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 11;16(10):1321.
doi: 10.3390/pharmaceutics16101321.

Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review

Tayná F G S Bandeira  1 , Luciana C Marti  2 , Edna T Rother  2 , Lucas Reis Correia  1 , Clarisse M Machado  3
Affiliations
Review

Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review

Tayná F G S Bandeira et al. Pharmaceutics. .

Abstract

Cytomegalovirus (CMV) poses a significant threat to post-hematopoietic cell transplantation (HCT). Control strategies include letermovir prophylaxis or ganciclovir pre-emptive therapy (PET). Without prophylaxis, 65-90% of seropositive recipients develop a clinically significant CMV infection. Due to PET drawbacks, letermovir prophylaxis is preferable, as it reduces CMV-related events and improves overall survival. However, refractory or resistant CMV-CS remains a challenge, with maribavir showing limited efficacy. This systematic review followed the Cochrane Manual and PRISMA guidelines and was registered in PROSPERO. Searches were conducted in PubMed, Scopus, Embase, and Web of Science. Out of 1895 identified records, 614 duplicates were removed, and subsequent screening excluded 1153 studies. Eleven included studies (2012-2024) involved 255 HCT recipients receiving adoptive immunotherapy (AI), primarily CMV-specific T-cell therapy. GvHD occurred in 1.82% of cases. Adverse events occurred in 4.4% of cases, while mild CRS was observed in 1.3% of patients. Efficacy, evaluated in 299 patients across eleven studies, showed an average response rate of 78.2%. CMV-CS recurrence was observed in 24.4% of 213 patients, and death due to CMV was reported in 9.7% of 307 patients across nine studies. Adoptive hCMV-specific T-cell immunotherapy appears to be a safe, effective alternative for refractory CMV-CS in HCT.

Keywords: cytomegalovirus infection; hematopoietic cell transplant; specific T lymphocytes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study selection flowchart.
Figure 2
Figure 2
Risk of bias of the included articles according to ROBINS-I [20,21,22,23,24,25,26,27,28,29,30].
See this image and copyright information in PMC

References

    1. Camargo J.F., Komanduri K.V. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol. Oncol. Stem Cell Ther. 2017;10:233–238. doi: 10.1016/j.hemonc.2017.05.001. - DOI - PubMed
    1. Machado C.M., Dulley F.L., Boas L., Castelli J.B., Macedo M.C.A., Silva R.L., Pallota R., Pannuti C.S. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy. Bone Marrow Transpl. 2000;26:413–417. doi: 10.1038/sj.bmt.1702526. - DOI - PubMed
    1. Kerbauy M.N., Ribeiro A.A.F., Arcuri L.J., Kerbauy L.N., da Silva C.C., Camargo L.F.A., Machado C.M., Hamerschlak N. Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 2021;23:e13626. doi: 10.1111/tid.13626. - DOI - PubMed
    1. Chemaly R.F., El Haddad L., Winston D.J., Rowley S.D., Mulane K.M., Chandrasekar P., Avery R.K., Hari P., Peggs K.S., Kumar D., et al. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clin. Infect. Dis. 2020;71:2365–2374. doi: 10.1093/cid/ciz1210. - DOI - PMC - PubMed
    1. Boeckh M., Bowden R.A., Gooley T., Myerson D., Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood J. Am. Soc. Hematol. 1999;93:1781–1782. - PubMed

LinkOut - more resources